Take­da tees up $420M deal for celi­ac an­ti­dote, con­tin­u­ing R&D re­fo­cus

Some­time in the 1st cen­tu­ry AD, a pa­tient pre­sent­ed to Arataeus look­ing like a vari­cose ghost. He was “ema­ci­at­ed and at­ro­phied, pale, fee­ble and in­ca­pable …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER